Solid Biosciences Archives -

The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a deal

Solid Biosciences acquires AavantiBio, conducts $75 million private placement

https://pharmaphorum.com/news/solid-biosciences-acquires-aavantibio-conducts-75-million-private-placement/

New data on Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) has gone a long way towards building

Myocarditis case mars Sarepta DMD gene therapy readout

https://pharmaphorum.com/news/myocarditis-case-mars-sarepta-dmd-gene-therapy-readout/

The development of gene therapies for Duchenne muscular dystrophy has proved to be challenging, but one of the

Sarepta says early filing for DMD gene therapy may be back on

https://pharmaphorum.com/news/sarepta-says-early-filing-for-dmd-gene-therapy-may-be-back-on/

Pfizer has called a halt to a clinical trial of its gene therapy for Duchenne muscular dystrophy as

Pfizer pauses Duchenne gene therapy trial after patient death

https://pharmaphorum.com/news/pfizer-pauses-duchenne-gene-therapy-trial-after-patient-death/

The FDA has placed another clinical hold on a gene therapy for Duchenne muscular dystrophy developed by Solid

Solid Bio hit as FDA slaps clinical hold on DMD gene therapy

https://pharmaphorum.com/news/solid-bio-hit-as-fda-slaps-clinical-hold-on-dmd-gene-therapy/

Shares in two US gene therapy biotechs have fallen after two cutting-edge treatments failed to produce convincing results

Gene therapy biotech shares sink on inconclusive trial results

https://pharmaphorum.com/news/gene-therapy-biotech-shares-sink-on-inconclusive-trial-results/

Solid Biosciences